Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults Aged 18 Years and Over

Next Previous
Trial Profile

A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults Aged 18 Years and Over

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VTP 100 (Primary)
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Sponsors Barinthus Biotherapeutics

Most Recent Events

  • 06 Nov 2023 According to Barinthus Biotherapeutics media release, Vaccitech has changed its name to Barinthus Biotherapeutics
  • 23 Apr 2021 Status changed from active, no longer recruiting to discontinued as the trial is being stopped for futility, season 2 cancelled.
  • 31 Jan 2020 According to a Vaccitech media release, The committee analysis indicates that while the vaccine was safe and well tolerated, the trial is unlikely to meet the primary endpoint and achieve the required level of reduction in the incidence of laboratory-confirmed influenza in participants receiving VTP-100 as an add-on to a seasonal Quadrivalent Influenza Vaccine (QIV), relative to participants receiving VTP-100 as an add-on to a Quadrivalent Influenza Vaccine (QIV), relative to QIV alone.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top